CP60 Stock Chart & Stats
€63.20
€1.32(2.13%)
At close: 4:00 PM EDT
€63.20
€1.32(2.13%)
Day’s Range― - ―
52-Week Range€49.77 - €74.50
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
€12.23B
Enterprise Value€14.59K
Total Cash (Recent Filing)€138.80M
Total Debt (Recent Filing)€2.46B
Price to Earnings (P/E)61.3
Beta0.53
Next Earnings
Sep 09, 2026EPS Estimate
0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.18
Shares Outstanding195,030,620
10 Day Avg. Volume3
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio-8.14
Price to Book (P/B)1.70
Price to Sales (P/S)3.42
P/FCF Ratio32.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€67.41Price Target Upside6.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)4.07
Revenue Forecast (FY)€3.78B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthSizable equity base and moderate leverage (~0.30 D/E) provide durable financial flexibility. This supports investment in R&D, M&A, litigation funding and capital returns without stressing liquidity, helping the company execute strategy through cycles and preserve optionality over the next several years.
Market Leadership In LensesLeading market share and strength in daily silicone hydrogel lenses create sustainable competitive advantages: scale in manufacturing, distribution reach, and brand recognition. This supports pricing, new product rollout adoption and long-term organic growth across regions, supporting durable revenue base.
Clear FCF Targets & GuidanceManagement's multi-year free-cash-flow targets and FY2026 guidance indicate disciplined capital allocation and focus on cash generation. Sustained FCF supports debt reduction, reinvestment and potential returns to shareholders, anchoring long-term financial resilience and strategic optionality.
Bears Say
Margin DeteriorationMaterial step-down in net margins versus prior years signals weakening profitability quality. Persistently lower margins reduce internal reinvestment capacity and return on capital, increasing sensitivity to cost inflation or pricing pressure and lowering long-run earnings power if not reversed.
Weakened Cash ConversionSignificant decline in free cash flow and weaker operating cash conversion imply reduced cash earnings quality and higher working-capital needs. Persistently lower FCF constrains discretionary spending and strategic moves, reducing resilience to shocks and limiting long-term capital allocation flexibility.
Significant Litigation Cash DemandLarge litigation accrual and concentrated payouts in fiscal 2026 create lasting GAAP earnings volatility and redirect cash away from growth investments. Even if insured partially, these liabilities can depress reported results, tighten near-term liquidity and complicate execution of buybacks or M&A.
Cooper Co News
CP60 FAQ
What was Cooper Co’s price range in the past 12 months?
Cooper Co lowest stock price was €49.77 and its highest was €74.50 in the past 12 months.
What is Cooper Co’s market cap?
Cooper Co’s market cap is €12.23B.
When is Cooper Co’s upcoming earnings report date?
Cooper Co’s upcoming earnings report date is Sep 09, 2026 which is in 37 days.
How were Cooper Co’s earnings last quarter?
Cooper Co released its earnings results on Jun 04, 2026. The company reported €1.049 earnings per share for the quarter, beating the consensus estimate of €0.957 by €0.092.
Is Cooper Co overvalued?
According to Wall Street analysts Cooper Co’s price is currently Undervalued.
Does Cooper Co pay dividends?
Cooper Co does not currently pay dividends.
What is Cooper Co’s EPS estimate?
Cooper Co’s EPS estimate is 0.97.
How many shares outstanding does Cooper Co have?
Cooper Co has 195,030,620 shares outstanding.
What happened to Cooper Co’s price movement after its last earnings report?
Cooper Co reported an EPS of €1.049 in its last earnings report, beating expectations of €0.957. Following the earnings report the stock price went up 3.884%.
Which hedge fund is a major shareholder of Cooper Co?
Currently, no hedge funds are holding shares in DE:CP60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cooper Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€67.41 (6.67% Upside)
€67.41 (6.67% Upside)
Blogger Sentiment
Bullish
DE:CP60 Sentiment 66%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.55%
Trailing 12-Months
Company Description
Cooper Co
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
CP60 Company Deck
CP60 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive operational and financial picture: record quarterly revenue and strong non-GAAP EPS, meaningful margin expansion, robust product-level growth (notably MiSight and CooperSurgical fertility), improved free cash flow and active strategic initiatives. However, material near-term headwinds create caution — a significant litigation settlement affecting GAAP results and concentrated cash outflows, Asia Pacific market softness tied to legacy product rationalization and consumer weakness (especially Japan/China), and expected short-term gross margin pressure from FX, tariffs and inventory optimization. Management balanced conservative guidance with a clear plan for capital allocation and strategic review progress, leaving the near-term outlook mixed but supported by strong execution and long-term cash-generation targets.View all DE:CP60 earnings summariesCP60 Net sales Breakdown
67.05% CooperVision
32.95% CooperSurgical
CP60 Stock 12 Month Forecast
Average Price Target
€67.41
▲(6.67% Upside)